Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AGILENT TECHNOLOGIES, INC.

(A)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agilent Technologies : Completes the InfinityLab Bio LC Portfolio

06/22/2021 | 03:01am EDT

Launching the full range for biopharma analysis at the Agilent InfinityLab LC Virtual Conference

Agilent Technologies Inc. (NYSE: A) today announced the launch of three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release is central to the Agilent portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that seamlessly integrate with Agilent OpenLab and MassHunter software, and CrossLab services to maximize efficiency in biopharma labs.

The three new systems include the 1290 Infinity II Bio LC System with High-Speed Pump, the 1290 Infinity II Bio LC System with Flexible Pump, and the 1260 Infinity II Prime Bio LC System. These systems are based on the proven, award-winning InfinityLab LC technology and were designed to help future-proof laboratories by providing a universal LC platform that delivers InfinityLab LC reliability and performance with additional bio-analysis capability and even greater resistance to harsh analytical conditions.

"This is a significant portfolio release that further demonstrates Agilent's commitment to the fast-growing biopharma LC market," said Stefan Schuette, vice president, and general manager of Agilent’s Liquid Phase Separations Division. "By offering new instruments, columns, application kits, and supplies we're providing solutions that customers can tailor to meet their specific bio-analytical requirements, including seamless transfer of existing methods from both Agilent and non-Agilent LC systems.”

Agilent also announced the planned release of several new workflow solutions based on the Bio LC core systems. These specialized solutions include a new, biocompatible 2D-LC, method development, and a new Online LC solution for process monitoring and process analytical technology (PAT). These new solutions will complement already existing bio-analytical LC/Q-TOF MS, SEC (Size Exclusion Chromatography) and bio-purification solutions from Agilent.

The Bio LC portfolio launch takes center stage at the first InfinityLab LC Virtual Conference taking place on 22nd – 23rd June 2021. For more information, visit the event registration page.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.


© Business Wire 2021
All news about AGILENT TECHNOLOGIES, INC.
07/28AGILENT TECHNOLOGIES INC. : - Clinical Utility of ALK Fusion Detection by Liquid..
AQ
07/28AGILENT TECHNOLOGIES : Early Career Professor Award Presented to Jason H. Yang
BU
07/27AGILENT TECHNOLOGIES : Clinical Utility of ALK Fusion Detection by Liquid Biopsy
BU
07/22AGILENT TECHNOLOGIES : Celebrates More than 20 Years of Sustainable Progress
BU
07/21AGILENT TECHNOLOGIES : to Webcast Third-Quarter Fiscal Year 2021 Financial Resul..
BU
07/20Agilent Technologies PharmDx Assay Receives Expanded Use in EU
MT
07/20Agilent Technologies Inc. Announces That the PD-L1 IHC 22C3 PharmDx Assay Is ..
CI
07/20AGILENT TECHNOLOGIES : PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small C..
PU
07/20Thomas Scientific Lands Agilent as Distribution Partner
CI
07/20Agilent Announces the Availability of an Optimized and Verified Method for Te..
CI
More news
Financials (USD)
Sales 2021 6 221 M - -
Net income 2021 1 039 M - -
Net Debt 2021 1 487 M - -
P/E ratio 2021 45,2x
Yield 2021 0,51%
Capitalization 46 497 M 46 497 M -
EV / Sales 2021 7,71x
EV / Sales 2022 7,27x
Nbr of Employees 16 500
Free-Float 99,3%
Chart AGILENT TECHNOLOGIES, INC.
Duration : Period :
Agilent Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGILENT TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 153,23 $
Average target price 146,31 $
Spread / Average Target -4,51%
EPS Revisions
Managers and Directors
Michael R. McMullen President, Chief Executive Officer & Director
Robert W. McMahon Chief Financial Officer & Senior Vice President
Koh Boon Hwee Non-Executive Chairman
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Katharine Knobil Chief Medical Officer
Sector and Competitors